|
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
- The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
- Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα
- Current Issue | New England Journal of Medicine
Explore the current issue of The New England Journal of Medicine (Vol 393 No 21)
- Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP
- Highly Pathogenic Avian Influenza A(H5N1) Virus Infections in Humans
Highly pathogenic avian influenza A(H5N1) viruses have caused widespread infections in dairy cows and poultry in the United States, with sporadic human cases We describe characteristics of human A
- Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Methods In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise
- Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual Current disease-modifying therapies for multiple sclero
|
|
|